Relevant bibliographies by topics / Lymphatic filariasis

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Lymphatic filariasis'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Lymphatic filariasis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Lymphatic filariasis"

1

Bradley, J. E. "Lymphatic filariasis." Transactions of the Royal Society of Tropical Medicine and Hygiene 94, no. 3 (May 2000): 350. http://dx.doi.org/10.1016/s0035-9203(00)90351-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Andrade, Mauro. "Lymphatic Filariasis." Problems in General Surgery 18, no. 4 (December 2001): 79–83. http://dx.doi.org/10.1097/00013452-200112000-00013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lourens, Gayle B., and Denise K. Ferrell. "Lymphatic Filariasis." Nursing Clinics of North America 54, no. 2 (June 2019): 181–92. http://dx.doi.org/10.1016/j.cnur.2019.02.007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ichimori, Kazuyo. "MDA—Lymphatic Filariasis." Tropical Medicine and Health 42, no. 2SUPPLEMENT (2014): S21—S24. http://dx.doi.org/10.2149/tmh.2014-s03.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Voelker, R. "Fighting Lymphatic Filariasis." JAMA: The Journal of the American Medical Association 280, no. 22 (December 9, 1998): 1898—a—1898. http://dx.doi.org/10.1001/jama.280.22.1898-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Voelker, Rebecca. "Fighting Lymphatic Filariasis." JAMA 280, no. 22 (December 9, 1998): 1898. http://dx.doi.org/10.1001/jama.280.22.1898-jwm80009-2-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Streit, Thomas, and Jack Guy Lafontant. "Eliminating Lymphatic Filariasis." Annals of the New York Academy of Sciences 1136, no. 1 (July 25, 2008): 53–63. http://dx.doi.org/10.1196/annals.1425.036.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Marsden, P. D. "Obstructive lymphatic filariasis." BMJ 306, no. 6870 (January 9, 1993): 136. http://dx.doi.org/10.1136/bmj.306.6870.136.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Simonsen, Paul E., and Mbutolwe E. Mwakitalu. "Urban lymphatic filariasis." Parasitology Research 112, no. 1 (December 13, 2012): 35–44. http://dx.doi.org/10.1007/s00436-012-3226-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ramadhani, Tri. "Filariasis Limfatik di Kelurahan Pabean Kota Pekalongan." Kesmas: National Public Health Journal 3, no. 2 (October 1, 2008): 51. http://dx.doi.org/10.21109/kesmas.v3i2.229.

Full text
Abstract:
Filariasis limfatik masih merupakan masalah kesehatan masyarakat di Indonesia, khususnya di Kota Pekalongan. Hal ini ditandai dengan semakin meningkatnya angka mikrofilaria dan perluasan daerah dengan kasus filariasis limfatik.Tujuan penelitian adalah untuk mengetahui situasi filariasis limfatik diKelurahan Pabean Kota Pekalongan. Penelitian ini meliputi penduduk dan agent, dalam periode sekitar enam bulan (Juli-Desember 2007) dengan disain studi cross sectional. Pada penelitian ini dilakukan pemeriksaan klinis, survei darah jari dan identifikasi parasit penyebab filariasis limfatik. Hasil penelitian menunjukkan angka mikrofilaria (3,4) angka kesakitan akut filaria (0,4 %) yang tinggi, tetapi angka kesakitan kronis filaria rendah (0,00 %). Parasit penyebabfilariasis di Kelurahan Pabean adalah jenis Wuchereria bancrofti dengan kepadatan rerata mikrofilaria yang tinggi. Pengendalian filariasis limfatik di Kelurahan Pabean perlu dilakukan dengan pengobatan massal dan perubahan perilaku masyarakat.Kata kunci : Filariasis limfatik, kelurahan pabean, mikrofilaria.AbstractLymphatic filariasis is still being a public health problem in Indonesia, especially in Pekalongan district. This problem marked by the increasing rate of microfilaria and areas with lymphatic filariasis. The aim of this study is to know the epidemiologic situation of lymphatic filariasis in Pabean village Pekalongan district. The research was a cross-sectional design and covered host and agent within the period of July-Desember 2007. Data were collected through clinical survey of acute and chronic filariasis symptoms, blood survey and identification of lymphatic filariasis parasite. The result showed that microfilaremia rate was 3,4%, acute disease rate (ADR) 0,4 % and the chronic disease rate (CDR) 0,00 %. The average of microfilaria density in 1 ml blood was 465,63. Based onmicrofilaremia identification in the blood, the lymphatic filariasis agent in Pabean village is Wuchereria bancrofti type. Lymphatic filariasis control in Pabean village need to focused on Mass Drug Administration (MDA) and community behavior for healthy life.Key words : Lymphatic filariasis, pabean village, microfilaria.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Lymphatic filariasis"

1

Alexander, N. "Heterogeneity and the epidemiology of lymphatic filariasis." Thesis, University of Cambridge, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.595423.

Full text
Abstract:
The life cycle of the parasite and the consequent human disease manifestations are reviewed in Chapter 1. Chapter 2 describes the drug trial in Papua New Guinea which provides most of the data for the dissertation. Chapter 3 demonstrates that data on two aspects of the vector-human interface - density dependence of microfilarial survival, and comparisons of mosquito catching methods - have in the past been manipulated in ways which simplified analysis by reducing the influence of extreme values, but at the cost of unjustified conclusions. Chapter 4 analyses the mean and aggregation of human microfilarial density as functions of age and sex. In particular, data from demographic surveillance are used to investigate the hypothesis that a drop in intensity among women of reproductive age is the result of pregnancy-associated changes. In addition, spatial heterogeneity is shown to be an alternative explanation for intra-family associations which have previously been attributed to in utero effects. The distributions of acute and chronic disease are characterized in Chapters 5 and 6, in order to select statistical models which can accommodate heterogeneity and determine risk factors for the different types of morbidity. Geographical patterns are visualized using satellite mapping techniques, and autoregressive spatial models are used to check that the maps are not unduly dominated by counts with high sampling variability because of small denominators. Chapter 7 returns to the vector to consider possible effects on other mosquito-borne diseases of mass anti-filarial chemotherapeutic control programmes. Chapter 8 provides a concluding synthesis of the work. Overall, this research demonstrates that heterogeneity arises in lymphatic filariasis through a network of factors - including vector contact, innate and acquired host characteristics, and geographical variability - which must be recognized and distinguished in order to properly quantify the epidemiology of the disease.
APA, Harvard, Vancouver, ISO, and other styles
2

Mohammed, Khalfan A. "Lymphatic filariasis in Zanzibar : epidemiology, elimination and impact." Thesis, University of Liverpool, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.507504.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kyelem, Dominique. "Epidemiology and control of lymphatic filariasis in Burkina Faso." Thesis, University of Liverpool, 2007. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.439478.

Full text
Abstract:
This thesis presents the work divided in three main areas: 1) the distribution of Lymphatic Filariasis caused by Wuchereria bancrofti and the non-pathogenic filarial parasite Mansonella perstans; 2) the implementation of a public health programme to eliminate LF describing the activities and discussing the impact of the programme, and 3) the assessment of the cost of the NPELF. This study was the first to provide countrywide epidemiological data on W. bancrofti and M. perstans infections in Burkina Faso as well as in some other West African countries. All the 55 health districts were mapped using immunochromatographic card tests for filarial antigenaemia detection. All the 102 sampled villages were positive except one. The prevalence ranged from 2% to 74% and the overall prevalence was 29.2%. W. bancroft; microfilaraemia baseline in sentinel sites showed an overall prevalence of 8.2% and the average mean density was 1108mf/ml in positive subjects. Children under 5 years presented 0.6% W. bancrofti microfilaraemia prevalence. The urban distribution of W. bancrofti showed a lower prevalence for antigenaemia (2.3%) and microfilaraemia (0.7%). Hydrocoele prevalence in males 15 years and above was 7.2% while lymphoedema was found in 0.6% of the 13 492 surveyed individuals. M. perstans has also been found to be widely distributed in the country with an overall prevalence of 5.9%. The impact of the onchocerciasis control programme activities using the distribution of ivermectin alone for 6 and 14 years in two different sites in Burkina Faso was also studied. It was concluded that 6-year treatment with ivermectin alone might have significantly reduced the prevalence of W. bancrofti whilst it appears that up to 14 years annual or twice-annual treatment with ivermectin may have stopped W. bancrofti transmission. These findings have implications for many areas of Africa where onchocerciasis and LF are co-endemic and the APOC programme has created sustained ivermectin distribution programmes. This thesis documented the impact of 2 to 5 rounds of mass drug administration using albendazole and ivermectin following the implementation of the national programme to eliminate lymphatic filariasis. Although, yearly treatment coverage (69% to 77%) never reached the recommended 80% coverage of total population a significant decline in community microfilaraemia prevalence (up to 95%) and density (up to 98%) has been observed in all sentinel sites except one. In general, there were no significant changes in M. perstans prevalence and density after 2 to 5 annual treatments. Monitoring results showed that reported and checked coverage were largely consistent in the rural and semi-urban districts but not in the urban settings. In addition, there was relative low prevalence of side effects following treatments. Lymphatic filariasis transmission knowledge was poor and the main reason for not taking the drugs was absenteeism. The cost analysis of the programme demonstrated that the start-up financial cost per person treated was US$ 0.11 as the programme is using the existing health system including community volunteers. The studies carried out in this thesis suggest that the GPELF recommended strategy is effective; however, used by and within a national public health system of a "developing" country elimination may need more time than the anticipated four to six years. The required improvement of the social mobilisation component remains a challenge for the success of the programme, especially in urban settings.
APA, Harvard, Vancouver, ISO, and other styles
4

Kassis, Timothy. "Quantifying the role of lymphatics in lipid transport and lymphatic filariasis using novel engineering approaches." Diss., Georgia Institute of Technology, 2015. http://hdl.handle.net/1853/53921.

Full text
Abstract:
The lymphatic system has fundamental physiological roles in maintaining fluid homeostasis, immune cell trafficking and lipid transport from the small intestine to the venous circulation. Lymphatic vessels are the main functional organ responsible for the diverse transport roles the system plays. Unlike the blood vasculature, the lymphatic system does not have a central pump, such as the heart, and relies on a variety of factors to move lymph through. It was long thought that only external factors, such as skeletal muscle contraction and lymph formation, played a role in the functional transport capacity of these vessels. With the advancement of imaging capabilities (both hardware and software), it has become clear in the past two decades or so that the main factor in driving lymph transport is the ability of these vessels to intrinsically contract whereby each vessel is comprised of a chain of ‘mini pumps’ in series. The functional capacity of these vessels is thus now understood to be primarily determined by this pumping activity that has been shown to be regulated by various mechanical and biochemical cues. Lymphatic vessel dysfunction has been implicated in a variety of diseases including many lipid related pathologies and a neglected tropical disease known as lymphatic filariasis. While it has been possible to study the vessel function in the context of fluid drainage and immune cell trafficking, the capability to understand the role of lymphatic vessels in lipid transport has not been available due to the lack of experimental animal models and acquisition systems. As part of this thesis, we sought to develop an experimental animal model along with hardware and software tools to investigate the interplay between lymphatics and their lipid content. We report the first functional measurements of how vessels respond to elevated lipid loads. We further utilized our engineering expertise to develop an experimental platform allowing us to further understand the parasite known as B. malayi that migrates to and resides in lymphatic vessels.
APA, Harvard, Vancouver, ISO, and other styles
5

Malecela, Mwelecele Ntuli Nyagwa. "The immune response and microfilaria in cats infected with B. pahangi." Thesis, London School of Hygiene and Tropical Medicine (University of London), 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.283720.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Biritwum, Nana-Kwadwo. "Lymphatic filariasis elimination : platform for neglected tropical disease control in Ghana." Thesis, University of Liverpool, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.631713.

Full text
Abstract:
The World Health Assembly resolution (WHA 50.29) called for the elimination of lymphatic filariasis (LF) as a public health problem and set in motion a series of global, regional and country activities aimed at the achievement of this objective, the guiding principle of Ghana's programme to eliminate LF. The main goal of this study is to determine the impact of mass drug administration (MDA) on the prevalence and transmission intensity of LF and investigate the suitability of the community directed approach as a vehicle for developing an integrated treatment strategy and plan targeting other neglected tropical diseases (NTDs) amenable to MDA within the context of the health system. To determine the impact of the Ghana Filariasis Elimination Programme on LF elimination and on other NTDs amenable to MDA and the health system Ghana has an estimated population of 25 million and is endemic for all the diseases targeted with preventive chemotherapy. The country has been mapped for all these diseases. The Lymphatic Filariasis Elimination Programme, serving as an implementation platform, has made significant impacts on the epidemiology, implementation of LF elimination and implementation of other NTDs and within overall health system service provision. These diseases are LF, onchocerciasis, soil transmitted helminthiasis, schistosomiasis and trachoma.
APA, Harvard, Vancouver, ISO, and other styles
7

Tafatatha, Terence Thawe. "Lymphatic filariasis control in an HIV endemic area in northern Malawi." Thesis, University of Liverpool, 2018. http://livrepository.liverpool.ac.uk/3028723/.

Full text
Abstract:
Lymphatic filariasis (LF) and human immunodeficiency virus (HIV) are major public health problems in Malawi. Coinfections are widespread and there is possibility of important interactions between these two pathogens with consequences for LF control and elimination. There is little available evidence on co-infection and interaction of LF and HIV infections and the study set out to investigate associations and interactions between these two pathogens and determine possible consequences for LF control and elimination through annual mass drug administration (MDA). This thesis presents results from adult study participants in two rural sites in Karonga district, northern Malawi, a region endemic for both LF and HIV. Stored blood samples and data from two geographically separate studies were used. One was a clinical trial of anti-filarial agent dosing regimens in Songwe in the northern part of the district (the Songwe clinical trial), and the other a whole population annual HIV sero-survey with longitudinal follow up data from the southern part of the district (the Karonga Health and Demographic Surveillance System or KHDSS). The main objectives were: 1. To determine the prevalence of LF and HIV co-infections as quantified by the Og4C3 ELISA in a large cross-sectional study in Karonga district, rural northern Malawi. 2. To investigate whether higher and/or more frequent doses of albendazole and ivermectin were more effective in eliminating Wuchereria bancrofti microfilariae than the World Health Organisation (WHO) approved standard regimen. 3. To determine the relationship of circulating filarial antigen (CFA) and microfilaria count (MF) by HIV status. 4. To monitor the impact of Mass Drug Administration (MDA) on LF antigenaemia by HIV status by following a cohort of LF antigen positive individuals identified in objective one. 5. To assess the contribution of insecticide treated bed nets (ITNs) to changes in CFA. These objectives were met through three filarial research studies using data from two distinct geographical locations: Study 1, cross-sectional assessment of the relationship of HIV and markers of LF infection; Study 2, clinical trial of anti-filarial dosing regimens and Study 3, longitudinal assessment of the impact of MDA on LF antigenaemia by HIV status. In study 1 (cross-sectional assessment), 1,851 consecutive adult volunteers from the Songwe area of Karonga district were screened for HIV and LF infection. Overall CFA prevalence was 24.1% (447/1851) while CFA prevalence was 25.4% (43/169) in HIV-positive and 23.6% (351/1487) in HIV-negative participants (p=0.57). Geometric mean concentrations (GMC) of CFA were 859 and 1660 antigen units per ml of blood (Ag/ml) respectively, geometric mean ratio (GMR) 0.85, 95% CI 0.49-1.50. In addition, a further 7,863 adults from the KHDSS part of the district had an overall CFA prevalence of 23.8% (1875/7863), a CFA prevalence of 20.9% (86/411) in HIV-positive and 24.0% (1789/7452) in HIV-negative participants (p=0.15) at baseline. GMC CFA was 630 and 839 Ag/ml respectively (GMR 0.75, 95% CI 0.60-0.94). In the HIV-positive group, antiretroviral therapy (ART) use was associated with a lower CFA prevalence, 12.7% (18/142) vs. 25.3% (67/265), (OR 0.43, 95% CI 0.24-0.76). Prevalence of CFA decreased with duration of ART use, 15.2% 0-1 year (n=59), 13.6% > 1-2 years (n=44), 10.0% > 2-3 years (n=30) and 0% > 3-4 years treatment (n=9), p < 0.01 ?2 for linear trend. In study 2 (clinical trial), seventy individuals with confirmed circulating LF antigen had microfilarial counts > 80 microfilariae/ml and were randomised as part of a controlled open label clinical trial. The clinical trial compared three modified treatment groups to standard dosage of ivermectin and albendazole in adults. Participants were followed up every six months for two years for repeat microfilarial counts and safety assessments. All treatment groups achieved a significant reduction of microfilariae levels by 12 and 24 months of follow up. Doubling the standard dose and giving it twice yearly showed a non-significant tendency towards faster and more complete clearance. There were no serious adverse reactions. In study 3 (longitudinal assessment), the cohort was derived from study 1 and comprised of 1722 baseline CFA positive individuals who had a follow up blood sample and a random sample of 939 baseline CFA negative individuals. Of the 1722 baseline CFA positive individuals, 524 (30.4%) remained CFA-positive, a clearance rate of 325/1000 person years of follow up while all but two of the 939 CFA-negative individuals at baseline remained negative at follow up, an incidence of 1/1000 person years of follow up. Using logistic regression, two doses of annual MDA was independently associated with decreased CFA positivity while bed net ownership and HIV status were not associated with CFA positivity. In the HIV-positive subgroup, ART use did not show any association with CFA positivity at follow up. This is the first investigation of this magnitude into HIV and LF co-infection in Malawi and it adds significantly to existing knowledge in the field. The cross-sectional study of two distinct LF-exposed populations confirms that there is no evidence that HIV infection has an impact on LF epidemiology that will interfere with LF control measures. A significant association of ART use with lower CFA prevalence merits further investigation to understand this apparent beneficial impact of ART. At follow up, MDA effectively reduced CFA prevalence and worm burden and the effectiveness of MDA treatment is unaffected by HIV co-infection and ART status.
APA, Harvard, Vancouver, ISO, and other styles
8

Riley, S. "Methods of inference for high variance within-host models of lymphatic filariasis." Thesis, University of Oxford, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.249225.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hafiz, Israt. "Investigation of lymphatic filariasis distribution, morbidity management and disability prevention in Bangladesh." Thesis, University of Liverpool, 2018. http://livrepository.liverpool.ac.uk/3027338/.

Full text
Abstract:
Lymphatic filariasis (LF), a mosquito-borne parasitic disease, is a major cause of disability in Bangladesh with an estimated 70 million people at risk of infection and tens of thousands suffering from the main clinical conditions. LF is targeted for elimination as part of the Global Programme to Eliminate LF (GPELF), which aims to interrupt transmission through mass drug administration (MDA) and providing patient care to those affected through morbidity management and disability prevention (MMD). Since 2001, the National LF Elimination Programme in Bangladesh has successfully scaled up MDA and of interrupted transmission. More recently the LF Programme has focussed on MMDP strategies, however there were significant gaps in knowledge, little understood about the distribution of disease and local communities and health workers. In this context, this research project aimed to address the current status of LF disability and its management including i) to examine the historical distribution of clinical cases in an endemic district, ii) determine the number and prevalence of LF after MDA activities, iii) to determine the knowledge, attitude, practices (KAP) of community members and patients and iv) to assess the workload, experience and perspectives of community health workers (CHWs) for morbidity control in a highly endemic district. The descriptive and statistical analysis of historical data in Nilphamari district found that cases of lymphoedema were widespread and cases of hydrocoele were more clustered in one area of the district. Women were more affected by lymphoedema and men by hydrocoele, and older people were more affected by clinical condition and people with more advanced disease suffered from more acute attacks. A cluster survey conducted in Nilphamari district after MDA activities in 2012, including 1242 people found low prevalence of clinical cases LF with very few cases especially in people less than 30 years old and the leg being the most affected body part. Women were more affected by lymphoedema and men by hydrocoele. A KAP study conducted in the same district demonstrated that community members and people affected by LF were aware of the National LF Programme and some measures to care for themselves. However, despite good awareness campaign by National LF Programme it was revealed that there is practice of some inappropriate and unhygienic measures like cutting by fish bones/knife and Jharfoak (A local term meaning traditional healing based on people's belief). A KAP study conducted on CHW revealed that knowledge about MDA and morbidity control was impressive before any large scale MMDP activities. However, the CHWs expressed that they have too much workload, inadequate training and lack of incentives for good practice related to morbidity control. These results will help the National Programme better understand the distribution of clinical disease and what practices to put in place. Bangladesh is progressing well towards the elimination of LF. At this stage national programme will need to demonstrate that services are integrated into health systems for long term sustainable support for patients - as their condition are chronic and many individuals will remain affected for many more decades. This study result will provide guidance on where to focus targeted activities on morbidity control and how best to utilize the CHW to integrate.
APA, Harvard, Vancouver, ISO, and other styles
10

Koroma, J. B. "Preventive chemotherapy for elimination of lymphatic filariasis and onchocerciasis in Sierra Leone." Thesis, University of Liverpool, 2017. http://livrepository.liverpool.ac.uk/3008028/.

Full text
Abstract:
Lymphatic filariasis (LF) and onchocerciasis are highly endemic in Sierra Leone. Using World Health Organization (WHO) guidelines for monitoring national programmes where both infections are co-endemic, this study aimed to determine the impact of preventive chemotherapy on transmission intensity by measuring changes in human infection status using standard epidemiological indicators. Separate longitudinal studies designed to deliver WHO outcomes for programmes targeting the elimination of both diseases were conducted. Onchocerciasis mapping surveys from 1988-2005 revealed that twelve of fourteen health districts were endemic. The baseline average mf prevalence was 53.1%, and mf densities in positive-only or entire populations were 28.87 and 15.33 mf/snip, respectively. Mf prevalence and density increased with age and was higher in males than females. Baseline prevalence and intensity surveys showed that LF was endemic in all 14 districts (Wuchereria bancrofti antigenaemia prevalence > 1%). Mean LF prevalence by ICT cards was 21% (males 28%; females 15%) with higher prevalence in the northeast (Bombali 52%; Koinadugu 46%; Tonkolili 37%; Kono 30%) and lower in the southwest (Bonthe 3%; Pujehun 4%). Mf prevalence was also relatively higher in the northeast (Bombali 6.7%; Koinadugu 5.7%; Port Loko 4.4%; Kono 2.4%). Mf prevalence was higher in males (males 2.9%; females 1.8%) and infection rate was higher in the over 20 years age-group (2.5%) than younger (1.7%). Arithmetic mean mf density was 50.30 mf/ml among mf-positive individuals and 1.19 mf/ml in the population examined. Nationwide mass drug administration (MDA) using ivermectin plus albendazole was applied to eliminate both diseases. In 2010, after five rounds of MDA (2005-2009) with effective treatment coverage for onchocerciasis during 4/5 years, overall onchocerciasis mf prevalence was reduced by 60.26% (from 53.10% to 21.10%), overall mf density among positive-only individuals was reduced by 71.29% (28.87 to 8.29 mf/snip) and overall mf density among the entire population studied was reduced by 88.58% (15.33 to 1.75 mf/snip). Mf prevalence and density were higher in males, lowest in the 1-9 and highest in the 40-49 year age groups. Mf prevalence was reduced by >50% in 10/12 districts, and reduction in skin mf density was ≥50% among positives-only in 11/12 districts. After MDAs with effective treatment coverage in 2008-2010, LF mf prevalence decreased to less than 1% in 11/12 districts. Mf prevalence fell by 88.5% to 0.3%, with decreases of 70-95% in seven and 100% (0 prevalence) in four districts, respectively. Overall arithmetic mean mf density after three MDAs was 17.59 mf/ml among mf positive individuals and 0.05 mf/ml for the entire population examined. After five MDAs, the overall mf prevalence was 0.54% and was higher in males (0.7%) than females (0.36%). Eight of twelve districts with < 1% mf prevalence passed the pre-transmission assessment survey (TAS) and therefore qualified for a TAS to determine whether MDA could be stopped. Four districts failed the pre-TAS: Koinadugu (0.98% i.e. close to 1%), Bombali (2.67%), Kailahun (1.56%) and Kenema (0%). Following WHO recommendations, Kenema and Kailahun districts were paired to form a unit of approximately one million. Kenema, the spot check site, was considered to have failed the pre-TAS even though the mf prevalence was 0% because Kailahun, the sentinel site, failed. A qualitative study examining the impact of the Ebola virus disease (EVD) outbreak on the NTD programme found that despite a one-year absence of interventions, two rounds of MDA had been completed, including one during the ongoing outbreak in May/June 2015. Although it compromised the likelihood of achieving the 2020 targets of LF elimination and Onchocerciasis control, the EVD outbreak has enhanced awareness about the important role of community volunteers in ensuring its success. While it may be the ‘endgame’ for LF, the NTD community and collaborating research institutions must address additional challenges if Onchocerciasis is to be eliminated from Sierra Leone.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Lymphatic filariasis"

1

Goel, Trilok Chandra, and Apul Goel. Lymphatic Filariasis. Singapore: Springer Singapore, 2016. http://dx.doi.org/10.1007/978-981-10-2257-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Tyagi, Brij Kishore, ed. Lymphatic Filariasis. Singapore: Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-13-1391-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lymphatic filariasis, the disease and its control. Geneva: World Health Organization, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Health, Palau Ministry of. Dossier for verification of elimination of lymphatic filariasis in the Republic of Palau. Palau]: Ministry of Health, Republic of Palau, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

WHO Expert Committee on Filariasis. Lymphatic filariasis: the disease and its control: Fifth report of the WHO Expert Commmittee on Filariasis. Geneva: World Health Organization, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Rajagopalan, P. K. Studies on lymphatic filariasis at Vector Control Research Centre, Pondicherry: Abstracts of papers published (1975-1990). Pondicherry: Vector Control Research Centre, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Shenoy, R. K. Perspectives of Indian medicinal plants in the management of lymphatic filariasis. New Delhi: Medicinal Plants Unit, Indian Council of Medical Research, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Goel, Trilok Chandra, and Apul Goel. Lymphatic Filariasis. Springer, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lymphatic Filariasis. New Delhi: Central Council for Research in Homoeopathy, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Goel, Trilok Chandra, and Apul Goel. Lymphatic Filariasis. Springer, 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Lymphatic filariasis"

1

da Rocha, Eliana Maria Mauricio, Gilberto Fontes, and John Patrick Ehrenberg. "Lymphatic Filariasis." In Arthropod Borne Diseases, 369–81. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-13884-8_24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rajan, T. V., and A. V. Grundlapalli. "Lymphatic Filariasis." In Chemical Immunology and Allergy, 125–58. Basel: KARGER, 1997. http://dx.doi.org/10.1159/000058668.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Goel, Trilok Chandra, and Apul Goel. "Lymphatic System." In Lymphatic Filariasis, 29–49. Singapore: Springer Singapore, 2016. http://dx.doi.org/10.1007/978-981-10-2257-9_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Reddya Naik, B. "Biological Control of Culex quinquefasciatus Say, 1823 (Diptera: Culicidae), the Ubiquitous Vector for Lymphatic Filariasis: A Review." In Lymphatic Filariasis, 281–92. Singapore: Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-13-1391-2_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Goel, Trilok Chandra, and Apul Goel. "History." In Lymphatic Filariasis, 3–5. Singapore: Springer Singapore, 2016. http://dx.doi.org/10.1007/978-981-10-2257-9_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Goel, Trilok Chandra, and Apul Goel. "Antifilarial Drugs." In Lymphatic Filariasis, 95–110. Singapore: Springer Singapore, 2016. http://dx.doi.org/10.1007/978-981-10-2257-9_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Goel, Trilok Chandra, and Apul Goel. "Clinical Manifestations of Filariasis." In Lymphatic Filariasis, 111–18. Singapore: Springer Singapore, 2016. http://dx.doi.org/10.1007/978-981-10-2257-9_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Goel, Trilok Chandra, and Apul Goel. "Filarial Fever." In Lymphatic Filariasis, 121–23. Singapore: Springer Singapore, 2016. http://dx.doi.org/10.1007/978-981-10-2257-9_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Goel, Trilok Chandra, and Apul Goel. "Acute Filarial Lymphangitis (AFL)." In Lymphatic Filariasis, 125–27. Singapore: Springer Singapore, 2016. http://dx.doi.org/10.1007/978-981-10-2257-9_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Goel, Trilok Chandra, and Apul Goel. "Acute Lymphadenitis (ADL)." In Lymphatic Filariasis, 129–32. Singapore: Springer Singapore, 2016. http://dx.doi.org/10.1007/978-981-10-2257-9_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Lymphatic filariasis"

1

Santoso, Yahya, Yanelza Supranelfy, and Nungki Hapsari Suryaningtyas. "Endemicity of Lymphatic Filariasis in Belitung Regency Post Elimination." In First International Conference on Health, Social Sciences and Technology (ICOHSST 2020). Paris, France: Atlantis Press, 2021. http://dx.doi.org/10.2991/assehr.k.210415.059.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Parsons, Kevin D., Timothy Kassis, and J. Brandon Dixon. "Design of an In Vitro Migration Chamber for Quantifying the Homing Patterns of Parasitic Worms." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80711.

Full text
Abstract:
Lymphatic filariasis, a parasitic disease often resulting in severe lymphatic dysfunction and lymphedema, is perpetuated by an invasion of worms, delivered through mosquito bites, that reside, mature, and reproduce in the human lymphatic system. The disease cycle begins with stage 3 larvae (L3) leaving the mosquito and penetrating the dermal layer of the human while the mosquito is feeding where it eventually makes its way to a collecting lymphatic vessel where it resides for its adult life (up to 10 years) [1]. While many infected individuals will remain asymptomatic, a subset of patients will develop reconstruction of the tissue structure and the extreme swelling of the arms, legs, genitals and/or breasts. This elephantiasis occurs in over 10 million people worldwide and has a harsh negative effect on the infected individual’s ability to work and function in society.
APA, Harvard, Vancouver, ISO, and other styles
3

Yahya, Tanwirotun Nimah, Reni Oktarina, and Santoso. "The Risk of Lymphatic Filariasis Transmission in Belitung Regency After Elimination Program." In First International Conference on Health, Social Sciences and Technology (ICOHSST 2020). Paris, France: Atlantis Press, 2021. http://dx.doi.org/10.2991/assehr.k.210415.006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Widawati, Mutiara, Endang Puji Astuti, Andri Ruliansyah, and Yuneu Yuliasih. "Sociodemographic, Knowledge, and Attitude Determinants of Lymphatic Filariasis Medication Adherence in Subang, Indonesia." In 5th Universitas Ahmad Dahlan Public Health Conference (UPHEC 2019). Paris, France: Atlantis Press, 2020. http://dx.doi.org/10.2991/ahsr.k.200311.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Prasetyowati, Heni, Muhammad Umar Riandi, Joni Hendri, and Mara Ipa. "Entomological Assessment in Tangerang, Indonesia: Post Transmission Assessment Survey of Lymphatic Filariasis Endemic Villages." In 5th Universitas Ahmad Dahlan Public Health Conference (UPHEC 2019). Paris, France: Atlantis Press, 2020. http://dx.doi.org/10.2991/ahsr.k.200311.012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ghiffari, Ahmad, Rini Pratiwi, Chairil Anwar, and Dalilah. "Monitoring Lymphatic Filariasis Interventions Through Adult Mosquito PCR Sampling in South Sumatra Province, Indonesia." In International Conference and the 10th Congress of the Entomological Society of Indonesia (ICCESI 2019). Paris, France: Atlantis Press, 2020. http://dx.doi.org/10.2991/absr.k.200513.039.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Rahayu, Nita, Yuniarti Suryatinah, Mara Ipa, Triwibowo Ambar Garjito, and Pandji Wibawa Dhewantara. "Identification of Filarial Parasites in Animals in Human Lymphatic Filariasis Endemic Areas in Central Kalimantan, Indonesia." In 4th International Symposium on Health Research (ISHR 2019). Paris, France: Atlantis Press, 2020. http://dx.doi.org/10.2991/ahsr.k.200215.124.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Siwiendrayanti, Arum, Eram Pawenang, Yuni Wijayanti, and Widya Cahyati. "Analysis of Lymphatic Filariasis Case Distribution for Preparing Environmental Based Elimination Strategy in Brebes Regency, Indonesia." In Proceedings of the 5th International Seminar of Public Health and Education, ISPHE 2020, 22 July 2020, Universitas Negeri Semarang, Semarang, Indonesia. EAI, 2020. http://dx.doi.org/10.4108/eai.22-7-2020.2300254.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tasman, H., T. Supali, A. K. Supriatna, N. Nuraini, and E. Soewono. "A mathematical model for long-term effect of diethylcarbamazine-albendazole mass drug administration on lymphatic filariasis." In SYMPOSIUM ON BIOMATHEMATICS (SYMOMATH 2014). AIP Publishing LLC, 2015. http://dx.doi.org/10.1063/1.4914445.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Rahayu, Nita, Yuniarti Suryatinah, M. Rasyid Ridha, Harninda Kusumaningtyas, Mara Ipa, and Pandji Wibawa Dhewantara. "Detecting Brugia Malayi in Lymphatic Filariasis Mosquito Vector in North Hulu Sungai District, South Kalimantan, Indonesia." In 4th International Symposium on Health Research (ISHR 2019). Paris, France: Atlantis Press, 2020. http://dx.doi.org/10.2991/ahsr.k.200215.034.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Lymphatic filariasis' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography